首页 > 最新文献

Dermatology最新文献

英文 中文
Artificial Intelligence-Driven Skin Aging Simulation as a Novel Skin Cancer Prevention. 人工智能驱动的皮肤老化模拟是一种新型皮肤癌预防方法。
IF 3 3区 医学 Q2 DERMATOLOGY Pub Date : 2025-01-01 Epub Date: 2024-10-14 DOI: 10.1159/000541943
Lorena Gantenbein, Sara Elisa Cerminara, Julia-Tatjana Maul, Alexander A Navarini, Lara Valeska Maul
<p><strong>Introduction: </strong>Skin cancer, a prevalent cancer type among fair-skinned patients globally, poses a relevant public health concern due to rising incidence rates. Ultraviolet (UV) radiation poses a major risk factor for skin cancer. However, intentional tanning associated with sunburns remains a common practice, notably among female adults. Appropriate prevention campaigns targeting children and adolescents are needed to improve sun protection behavior particularly in these age groups. The aim of our study was to investigate if an AI-based simulation of facial skin aging can enhance sun protection behavior in female adults.</p><p><strong>Methods: </strong>In this single-center, prospective, observational pilot study at Department of Dermatology at the University Hospital of Basel, we took photographs of healthy young females' faces with a VISIA-CR camera (Version 8.2; Canfield Scientific Inc., Parsippany, NJ, USA) between February and March 2021. Digital images were performed in three angles (straight, left 45°, and right 45°). All participants received an AI-based simulation of their facial skin with continuous aging to 80 years. A newly created anonymous questionnaire capturing participants' sociodemographic data and also tanning and sun protection behavior was completed in pre- and post-aging simulation. To observe long-term effects, a 2-year follow-up was conducted between March and April 2023.</p><p><strong>Results: </strong>The 60 participants (mean age 23.6 ± 2.5 years) evaluated the importance of sun protection significantly higher after skin aging simulation with VISIA-CR camera (p < 0.0001; 95% CI: 8.2-8.8). Post-intervention, 91.7% (55/60) of the females were motivated to reduce UV exposure and to intensify UV protection in the future since the individual UV-dependent risk was perceived significantly higher (p < 0.001; 95% CI: 5.9-6.7). At 2-year follow-up, 96% (24/25) indicated persistent effort reducing UV exposure. The preference for SPF 50+ sunscreen increased to 46.7% (28/65) directly after the skin aging simulation and continued to rise up to 60.0% (15/25) after 2 years.</p><p><strong>Conclusions: </strong>Our data emphasize the potential of AI-assisted photoaging interventions to enhance motivation for UV protection in the short and the long term. We encourage that different age and gender groups are addressed in a personalized, generation-specific manner with the appropriate media and by considering the Hawthorne effect. Campaigns with visual AI support can improve the intent of cancer-preventative behavior.</p><p><strong>Introduction: </strong>Skin cancer, a prevalent cancer type among fair-skinned patients globally, poses a relevant public health concern due to rising incidence rates. Ultraviolet (UV) radiation poses a major risk factor for skin cancer. However, intentional tanning associated with sunburns remains a common practice, notably among female adults. Appropriate prevention campaigns targeting childr
导言:皮肤癌是全球皮肤白皙的患者中常见的癌症类型,由于发病率不断上升,已成为一个相关的公共卫生问题。紫外线(UV)辐射是皮肤癌的主要风险因素。然而,与晒伤相关的故意晒黑仍是一种常见的做法,尤其是在成年女性中。 需要针对儿童和青少年开展适当的预防活动,以改善他们的防晒行为,尤其是在这些年龄组中。我们的研究旨在探讨基于人工智能的面部皮肤老化模拟是否能提高成年女性的防晒行为:在巴塞尔大学医院皮肤科进行的这项单中心前瞻性观察试点研究中,我们在 2021 年 2 月至 3 月期间使用 VISIA-CR 相机(Canfield Scientific Inc.数字图像从三个角度(直线、左 45°、右 45°)进行拍摄。所有参与者都接受了基于人工智能的面部皮肤模拟,并持续衰老至 80 岁。在模拟老化前后,参与者填写了一份新制作的匿名问卷,其中包括社会人口学数据以及日晒和防晒行为。为了观察长期效果,在 2023 年 3 月至 4 月期间进行了为期 2 年的跟踪调查:60名参与者(平均年龄为23.6±2.5岁)在使用VISIA-CR相机模拟皮肤老化后,对防晒重要性的评价明显提高(p<0.0001; 95%-CI:8.2-8.8)。干预后,91.7%(55/60)的女性有动力减少紫外线照射,并在未来加强紫外线防护,因为她们认为个人紫外线依赖风险明显增加(p<0.001; 95%-CI:5.9-6.7)。在两年的随访中,96%(24/25)的受访者表示将继续努力减少紫外线照射。皮肤老化模拟后,SPF50+防晒霜的偏好直接上升到46.7%(28/65),两年后继续上升到60.0%(15/25):我们鼓励针对不同年龄和性别的群体,通过适当的媒体和考虑霍桑效应,采取个性化的、针对特定世代的方式。有视觉人工智能支持的宣传活动可以提高防癌行为的积极性。
{"title":"Artificial Intelligence-Driven Skin Aging Simulation as a Novel Skin Cancer Prevention.","authors":"Lorena Gantenbein, Sara Elisa Cerminara, Julia-Tatjana Maul, Alexander A Navarini, Lara Valeska Maul","doi":"10.1159/000541943","DOIUrl":"10.1159/000541943","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;Skin cancer, a prevalent cancer type among fair-skinned patients globally, poses a relevant public health concern due to rising incidence rates. Ultraviolet (UV) radiation poses a major risk factor for skin cancer. However, intentional tanning associated with sunburns remains a common practice, notably among female adults. Appropriate prevention campaigns targeting children and adolescents are needed to improve sun protection behavior particularly in these age groups. The aim of our study was to investigate if an AI-based simulation of facial skin aging can enhance sun protection behavior in female adults.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;In this single-center, prospective, observational pilot study at Department of Dermatology at the University Hospital of Basel, we took photographs of healthy young females' faces with a VISIA-CR camera (Version 8.2; Canfield Scientific Inc., Parsippany, NJ, USA) between February and March 2021. Digital images were performed in three angles (straight, left 45°, and right 45°). All participants received an AI-based simulation of their facial skin with continuous aging to 80 years. A newly created anonymous questionnaire capturing participants' sociodemographic data and also tanning and sun protection behavior was completed in pre- and post-aging simulation. To observe long-term effects, a 2-year follow-up was conducted between March and April 2023.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The 60 participants (mean age 23.6 ± 2.5 years) evaluated the importance of sun protection significantly higher after skin aging simulation with VISIA-CR camera (p &lt; 0.0001; 95% CI: 8.2-8.8). Post-intervention, 91.7% (55/60) of the females were motivated to reduce UV exposure and to intensify UV protection in the future since the individual UV-dependent risk was perceived significantly higher (p &lt; 0.001; 95% CI: 5.9-6.7). At 2-year follow-up, 96% (24/25) indicated persistent effort reducing UV exposure. The preference for SPF 50+ sunscreen increased to 46.7% (28/65) directly after the skin aging simulation and continued to rise up to 60.0% (15/25) after 2 years.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Our data emphasize the potential of AI-assisted photoaging interventions to enhance motivation for UV protection in the short and the long term. We encourage that different age and gender groups are addressed in a personalized, generation-specific manner with the appropriate media and by considering the Hawthorne effect. Campaigns with visual AI support can improve the intent of cancer-preventative behavior.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;Skin cancer, a prevalent cancer type among fair-skinned patients globally, poses a relevant public health concern due to rising incidence rates. Ultraviolet (UV) radiation poses a major risk factor for skin cancer. However, intentional tanning associated with sunburns remains a common practice, notably among female adults. Appropriate prevention campaigns targeting childr","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"59-71"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11793091/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Frequency of Atopic Dermatitis and Psoriasis in the Elderly: Cross-Sectional Findings from the German AugUR Study. 老年人特应性皮炎和银屑病的发病率--德国 AugUR 研究的横断面结果。
IF 3 3区 医学 Q2 DERMATOLOGY Pub Date : 2025-01-01 Epub Date: 2024-09-27 DOI: 10.1159/000541590
Karl Philipp Drewitz, Klaus J Stark, Martina E Zimmermann, Iris M Heid, Christian J Apfelbacher
<p><strong>Introduction: </strong>Atopic dermatitis (AD) and psoriasis appear to affect 2-3% (lifetime prevalence) people worldwide. However, there are little epidemiological data on the prevalence of those two chronic inflammatory skin diseases in the elderly. The aim of this study was to provide frequency estimates of AD and psoriasis obtained from an elderly population in Germany.</p><p><strong>Methods: </strong>We examined baseline data from the AugUR study, a cohort study focusing on an aging population in the city and the vicinity of Regensburg, Germany. We estimated raw frequencies of physician-diagnosed AD and psoriasis from participants' self-reports in personal interviews. These frequencies were adjusted to reflect the demographic distribution of the Bavarian population, considering both sex and age groupings spanning 5 or 10 years and reported with 95% confidence interval (CI).</p><p><strong>Results: </strong>Data from 1,133 participants aged 70-95 (median age 76.7 years, 45.1% women) were available for analysis. Physician-diagnosed AD was reported by 3.3% (95% CI: 2.3-4.5) of participants (2.4% from men, 4.3% from women) and 5.6% (95% CI: 4.3-7.1%) reported physician-diagnosed psoriasis (6.6% in men, 4.3% in women). Age- and sex-standardized frequency estimates for AD were 3.4% (95% CI: 2.4-4.6, 2.6% in men, 4.3% in women) and 5.3% for psoriasis (95% CI: 4.1-6.8, 6.3% in men and 4.1% in women).</p><p><strong>Conclusion: </strong>This study indicates a lower than previously reported lifetime prevalence of AD (3.4% vs. 8-10%) and a higher one regarding psoriasis (5.3% vs. 2-4%) in highly aged individuals. More epidemiological research in elderly populations using validated physician diagnoses is desirable.</p><p><strong>Introduction: </strong>Atopic dermatitis (AD) and psoriasis appear to affect 2-3% (lifetime prevalence) people worldwide. However, there are little epidemiological data on the prevalence of those two chronic inflammatory skin diseases in the elderly. The aim of this study was to provide frequency estimates of AD and psoriasis obtained from an elderly population in Germany.</p><p><strong>Methods: </strong>We examined baseline data from the AugUR study, a cohort study focusing on an aging population in the city and the vicinity of Regensburg, Germany. We estimated raw frequencies of physician-diagnosed AD and psoriasis from participants' self-reports in personal interviews. These frequencies were adjusted to reflect the demographic distribution of the Bavarian population, considering both sex and age groupings spanning 5 or 10 years and reported with 95% confidence interval (CI).</p><p><strong>Results: </strong>Data from 1,133 participants aged 70-95 (median age 76.7 years, 45.1% women) were available for analysis. Physician-diagnosed AD was reported by 3.3% (95% CI: 2.3-4.5) of participants (2.4% from men, 4.3% from women) and 5.6% (95% CI: 4.3-7.1%) reported physician-diagnosed psoriasis (6.6% in men, 4.3% in women). Age
导言 特应性皮炎(AD)和银屑病似乎影响着全世界 2-3%(终生患病率)的人。然而,有关这两种慢性炎症性皮肤病在老年人中发病率的流行病学数据却很少。本研究的目的是提供德国老年人口中 AD 和银屑病发病率的估计值。方法 我们检查了 AugUR 研究的基线数据,这是一项针对德国雷根斯堡附近老龄人口的队列研究(共有 1,133 名参与者,中位年龄为 76.7 岁,45% 为女性)。我们根据参与者在个人访谈中的自我报告,估算出医生诊断为注意力缺失症和银屑病的原始频率。我们对这些频率进行了调整,以反映巴伐利亚州的人口分布情况,同时考虑到跨越 5 年或 10 年的性别和年龄分组。结果 有 1,133 名 70-95 岁的参与者(45.1% 为女性)的数据可供分析。3.3%的参与者(男性 2.4%,女性 4.3%)被医生诊断为注意力缺失症,5.6%(95%-CI:4.3-7.1%)的参与者(男性 6.6%,女性 4.3%)被医生诊断为银屑病。按年龄和性别标准化的发病频率估计值为:注意力缺失症为 3.4%(95%-CI:2.4-4.6,男性为 2.6%,女性为 4.3%),银屑病为 5.3%(95%-CI:4.1-6.8,男性为 6.3%,女性为 4.1%)。结论 本研究表明,在高龄人群中,注意力缺失症的终生患病率(3.4% 对 8-10%)和银屑病的终生患病率(5.3% 对 2-4%)均低于之前的报道。我们希望在老年人群中开展更多的流行病学研究,并使用有效的医生诊断方法。
{"title":"Frequency of Atopic Dermatitis and Psoriasis in the Elderly: Cross-Sectional Findings from the German AugUR Study.","authors":"Karl Philipp Drewitz, Klaus J Stark, Martina E Zimmermann, Iris M Heid, Christian J Apfelbacher","doi":"10.1159/000541590","DOIUrl":"10.1159/000541590","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;Atopic dermatitis (AD) and psoriasis appear to affect 2-3% (lifetime prevalence) people worldwide. However, there are little epidemiological data on the prevalence of those two chronic inflammatory skin diseases in the elderly. The aim of this study was to provide frequency estimates of AD and psoriasis obtained from an elderly population in Germany.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;We examined baseline data from the AugUR study, a cohort study focusing on an aging population in the city and the vicinity of Regensburg, Germany. We estimated raw frequencies of physician-diagnosed AD and psoriasis from participants' self-reports in personal interviews. These frequencies were adjusted to reflect the demographic distribution of the Bavarian population, considering both sex and age groupings spanning 5 or 10 years and reported with 95% confidence interval (CI).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Data from 1,133 participants aged 70-95 (median age 76.7 years, 45.1% women) were available for analysis. Physician-diagnosed AD was reported by 3.3% (95% CI: 2.3-4.5) of participants (2.4% from men, 4.3% from women) and 5.6% (95% CI: 4.3-7.1%) reported physician-diagnosed psoriasis (6.6% in men, 4.3% in women). Age- and sex-standardized frequency estimates for AD were 3.4% (95% CI: 2.4-4.6, 2.6% in men, 4.3% in women) and 5.3% for psoriasis (95% CI: 4.1-6.8, 6.3% in men and 4.1% in women).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;This study indicates a lower than previously reported lifetime prevalence of AD (3.4% vs. 8-10%) and a higher one regarding psoriasis (5.3% vs. 2-4%) in highly aged individuals. More epidemiological research in elderly populations using validated physician diagnoses is desirable.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;Atopic dermatitis (AD) and psoriasis appear to affect 2-3% (lifetime prevalence) people worldwide. However, there are little epidemiological data on the prevalence of those two chronic inflammatory skin diseases in the elderly. The aim of this study was to provide frequency estimates of AD and psoriasis obtained from an elderly population in Germany.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;We examined baseline data from the AugUR study, a cohort study focusing on an aging population in the city and the vicinity of Regensburg, Germany. We estimated raw frequencies of physician-diagnosed AD and psoriasis from participants' self-reports in personal interviews. These frequencies were adjusted to reflect the demographic distribution of the Bavarian population, considering both sex and age groupings spanning 5 or 10 years and reported with 95% confidence interval (CI).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Data from 1,133 participants aged 70-95 (median age 76.7 years, 45.1% women) were available for analysis. Physician-diagnosed AD was reported by 3.3% (95% CI: 2.3-4.5) of participants (2.4% from men, 4.3% from women) and 5.6% (95% CI: 4.3-7.1%) reported physician-diagnosed psoriasis (6.6% in men, 4.3% in women). Age","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-9"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11793095/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142343436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nodular Vasculitis: Retrospective Study of an Uncommon Disease in a Non-Tuberculosis Endemic Country with Focus on Treatment Modalities and Efficacy. 结节性血管炎--在一个非结核病流行国家对一种不常见疾病的回顾性研究,重点是治疗方法和疗效。
IF 3 3区 医学 Q2 DERMATOLOGY Pub Date : 2025-01-01 Epub Date: 2024-11-18 DOI: 10.1159/000542488
Carole Guillet, Xenia Hauser, Andrea Stillhard, Peter Schmid-Grendelmeier, Isabel Kolm
<p><strong>Introduction: </strong>Nodular vasculitis (NV) is a rare form of panniculitis primarily affecting middle-aged females, presenting as painful, sometimes ulcerated nodules on the dorsal lower legs. Erythema induratum of Bazin (EIB) is a form of NV and is considered a manifestation of cutaneous tuberculin hypersensitivity. This retrospective study aims to analyze demographics, clinicopathological findings, laboratory results, and treatment outcomes of NV in a non-TB endemic country.</p><p><strong>Methods: </strong>Data of NV patients were extracted from the electronic hospital database of the University Hospital Zurich. Patients were included only if histopathologically confirmed diagnosis of NV and sufficient information on demographics, treatment, and follow-up were available.</p><p><strong>Results: </strong>We conducted a 20-year retrospective study, including 62 patients with NV. The most common site of involvement was the lower extremities. Disease duration varied from several months to over 20 years. Histopathological examination revealed lobular panniculitis, with or without vasculitis, and granuloma formation. Tuberculosis association was assessed through the QuantiFERON test and mycobacteria PCR, showing positive results in 22 or 37 (59%) tested cases and in 2 out of 27 cases (7.4%), respectively. Comorbidities were found in over half of the patients. Treatment modalities included topical corticosteroids, antitubercular therapy, systemic steroids, and potassium iodide. Almost 50% of all patients experienced relapses despite treatment.</p><p><strong>Conclusion: </strong>Topical steroids, antitubercular therapy, systemic steroids, and potassium iodide showed similar response rates. Tuberculostatic therapy upon detecting latent TB is recommended. Considering the high recurrence rate and potential side effects of systemic therapies, we recommend first-line treatment with potent topical steroids and compression stockings.</p><p><strong>Introduction: </strong>Nodular vasculitis (NV) is a rare form of panniculitis primarily affecting middle-aged females, presenting as painful, sometimes ulcerated nodules on the dorsal lower legs. Erythema induratum of Bazin (EIB) is a form of NV and is considered a manifestation of cutaneous tuberculin hypersensitivity. This retrospective study aims to analyze demographics, clinicopathological findings, laboratory results, and treatment outcomes of NV in a non-TB endemic country.</p><p><strong>Methods: </strong>Data of NV patients were extracted from the electronic hospital database of the University Hospital Zurich. Patients were included only if histopathologically confirmed diagnosis of NV and sufficient information on demographics, treatment, and follow-up were available.</p><p><strong>Results: </strong>We conducted a 20-year retrospective study, including 62 patients with NV. The most common site of involvement was the lower extremities. Disease duration varied from several months to over 20 years.
导言结节性血管炎(NV)是一种罕见的泛发性血管炎,主要影响中年女性,表现为小腿背侧疼痛,有时会出现溃疡性结节。巴金红斑(EIB)是 NV 的一种形式,被认为是皮肤结核菌素过敏症的一种表现。这项回顾性研究旨在分析一个非结核病流行国家中 NV 的人口统计学特征、临床病理结果、实验室结果和治疗效果:方法:从苏黎世大学医院的电子医院数据库中提取 NV 患者的数据。只有经组织病理学确诊为非小细胞肺结核,并有足够的人口统计学、治疗和随访信息,患者才会被纳入其中:我们进行了一项为期 20 年的回顾性研究,共纳入 62 名 NV 患者。最常见的受累部位是下肢。病程从几个月到 20 多年不等。组织病理学检查显示,患者患有小叶性泛发性炎,伴有或不伴有血管炎和肉芽肿形成。通过定量FERON检测和分枝杆菌PCR检测评估了结核病的相关性,结果显示,分别有22例或37例(59%)和27例中的2例(7.4%)呈阳性。.超过一半的患者患有合并症。治疗方法包括局部皮质类固醇激素、抗结核治疗、全身性类固醇激素和碘化钾。尽管进行了治疗,但仍有近 50%的患者病情复发:结论:局部类固醇激素、抗结核疗法、全身类固醇激素和碘化钾的反应率相似。建议在发现潜伏肺结核时进行抗结核治疗。考虑到系统疗法的高复发率和潜在副作用,我们建议使用强效局部类固醇激素和弹力袜进行一线治疗。
{"title":"Nodular Vasculitis: Retrospective Study of an Uncommon Disease in a Non-Tuberculosis Endemic Country with Focus on Treatment Modalities and Efficacy.","authors":"Carole Guillet, Xenia Hauser, Andrea Stillhard, Peter Schmid-Grendelmeier, Isabel Kolm","doi":"10.1159/000542488","DOIUrl":"10.1159/000542488","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;Nodular vasculitis (NV) is a rare form of panniculitis primarily affecting middle-aged females, presenting as painful, sometimes ulcerated nodules on the dorsal lower legs. Erythema induratum of Bazin (EIB) is a form of NV and is considered a manifestation of cutaneous tuberculin hypersensitivity. This retrospective study aims to analyze demographics, clinicopathological findings, laboratory results, and treatment outcomes of NV in a non-TB endemic country.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Data of NV patients were extracted from the electronic hospital database of the University Hospital Zurich. Patients were included only if histopathologically confirmed diagnosis of NV and sufficient information on demographics, treatment, and follow-up were available.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;We conducted a 20-year retrospective study, including 62 patients with NV. The most common site of involvement was the lower extremities. Disease duration varied from several months to over 20 years. Histopathological examination revealed lobular panniculitis, with or without vasculitis, and granuloma formation. Tuberculosis association was assessed through the QuantiFERON test and mycobacteria PCR, showing positive results in 22 or 37 (59%) tested cases and in 2 out of 27 cases (7.4%), respectively. Comorbidities were found in over half of the patients. Treatment modalities included topical corticosteroids, antitubercular therapy, systemic steroids, and potassium iodide. Almost 50% of all patients experienced relapses despite treatment.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Topical steroids, antitubercular therapy, systemic steroids, and potassium iodide showed similar response rates. Tuberculostatic therapy upon detecting latent TB is recommended. Considering the high recurrence rate and potential side effects of systemic therapies, we recommend first-line treatment with potent topical steroids and compression stockings.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;Nodular vasculitis (NV) is a rare form of panniculitis primarily affecting middle-aged females, presenting as painful, sometimes ulcerated nodules on the dorsal lower legs. Erythema induratum of Bazin (EIB) is a form of NV and is considered a manifestation of cutaneous tuberculin hypersensitivity. This retrospective study aims to analyze demographics, clinicopathological findings, laboratory results, and treatment outcomes of NV in a non-TB endemic country.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Data of NV patients were extracted from the electronic hospital database of the University Hospital Zurich. Patients were included only if histopathologically confirmed diagnosis of NV and sufficient information on demographics, treatment, and follow-up were available.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;We conducted a 20-year retrospective study, including 62 patients with NV. The most common site of involvement was the lower extremities. Disease duration varied from several months to over 20 years.","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"27-34"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11793088/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognosis of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Cohort Study of 216 Patients in an Inpatient Dermatology Department. 史蒂文斯-约翰逊综合征和中毒性表皮坏死症的预后:对皮肤科住院病人中 216 名患者的队列研究。
IF 3 3区 医学 Q2 DERMATOLOGY Pub Date : 2025-01-01 Epub Date: 2024-11-27 DOI: 10.1159/000542623
Nguyen Dac Thuy Luong, Hoang Vuong Ngoc Duc, Thi Thuy Trang Vu, Khiem Hung Tran, Van Bac Pham

Introduction: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous adverse reactions. However, only a few studies have investigated the clinicodemographic and laboratory parameters predicting SJS and TEN outcomes other than mortality, such as severe complications or increased length of hospital stays. Our objectives are to identify admission risk factors predictive of severe complications and the accompanying clinical or biochemical markers associated with prolonged hospitalization.

Methods: A retrospective cohort study over a 9-year period (2013-2022).

Results: The study included 216 patients with SJS (n = 122), SJS/TEN overlap (n = 71), and TEN (n = 23). On multivariate analysis, the clinical factor on admission that was predictive of severe complications was blood urea nitrogen (BUN) >8.3 mmol/L (p = 0.007). Furthermore, BSA epidermal detachment >10% (p < 0.001), Severity-of-illness score for TEN (SCORTEN-1) ≥2 (p = 0.04), and positive skin culture (p = 0.04), from which the Prolonged Hospitalization Risk Score was created, were predictive of length of hospital stays >10 days. Using systemic methylprednisolone at a mean dose ≥1 mg/kg/day for a median duration of 10.5 days was not shown to increase or reduce complication rates of SJS/TEN and shorten hospital stays.

Conclusion: BUN >8.3 mmol/L present at admission is a risk factor for severe complications of SJS/TEN. BSA involvement >10%, SCORTEN-1 ≥2, and positive skin culture on admission are useful markers to predict extended hospitalization.

导言:史蒂文斯-约翰逊综合征(SJS)和中毒性表皮坏死(TEN)是严重的皮肤不良反应。然而,只有少数研究对预测 SJS 和 TEN 除死亡率以外的其他结果(如严重并发症或住院时间延长)的临床人口学和实验室参数进行了调查。我们的目标是确定可预测严重并发症的入院风险因素,以及与住院时间延长相关的临床或生化指标:方法:一项为期 9 年(2013-2022 年)的回顾性队列研究:研究纳入了216名SJS(122人)、SJS/TEN重叠(71人)和TEN(23人)患者。经多变量分析,入院时可预测严重并发症的临床因素是血尿素氮(BUN)> 8.3 mmol/L(P = 0.007)。此外,BSA 表皮脱落 >10 %(P < 0.001)、TEN 疾病严重程度评分(SCORTEN-1)≥ 2(P = 0.04)和皮肤培养阳性(P = 0.04)(根据这些因素创建了 "住院时间延长风险评分")也是住院时间超过 10 天的预测因素。使用全身甲基强的松龙的平均剂量≥1毫克/千克/天,中位持续时间为10.5天,但这并没有增加或减少SJS/TEN并发症的发生率,也没有缩短住院时间:结论:入院时BUN > 8.3 mmol/L是导致SJS/TEN严重并发症的危险因素。入院时 BUN > 8.3 mmol/L 是 SJS/TEN 严重并发症的危险因素,BSA 受累 > 10%、SCORTEN-1 ≥ 2 和皮肤培养阳性是预测住院时间延长的有用指标。
{"title":"Prognosis of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Cohort Study of 216 Patients in an Inpatient Dermatology Department.","authors":"Nguyen Dac Thuy Luong, Hoang Vuong Ngoc Duc, Thi Thuy Trang Vu, Khiem Hung Tran, Van Bac Pham","doi":"10.1159/000542623","DOIUrl":"10.1159/000542623","url":null,"abstract":"<p><strong>Introduction: </strong>Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous adverse reactions. However, only a few studies have investigated the clinicodemographic and laboratory parameters predicting SJS and TEN outcomes other than mortality, such as severe complications or increased length of hospital stays. Our objectives are to identify admission risk factors predictive of severe complications and the accompanying clinical or biochemical markers associated with prolonged hospitalization.</p><p><strong>Methods: </strong>A retrospective cohort study over a 9-year period (2013-2022).</p><p><strong>Results: </strong>The study included 216 patients with SJS (n = 122), SJS/TEN overlap (n = 71), and TEN (n = 23). On multivariate analysis, the clinical factor on admission that was predictive of severe complications was blood urea nitrogen (BUN) >8.3 mmol/L (p = 0.007). Furthermore, BSA epidermal detachment >10% (p < 0.001), Severity-of-illness score for TEN (SCORTEN-1) ≥2 (p = 0.04), and positive skin culture (p = 0.04), from which the Prolonged Hospitalization Risk Score was created, were predictive of length of hospital stays >10 days. Using systemic methylprednisolone at a mean dose ≥1 mg/kg/day for a median duration of 10.5 days was not shown to increase or reduce complication rates of SJS/TEN and shorten hospital stays.</p><p><strong>Conclusion: </strong>BUN >8.3 mmol/L present at admission is a risk factor for severe complications of SJS/TEN. BSA involvement >10%, SCORTEN-1 ≥2, and positive skin culture on admission are useful markers to predict extended hospitalization.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"49-58"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142738736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Developing a Core Outcome Set for Netherton Syndrome: An International Multi-Stakeholder e-Delphi Consensus Study. 为奈瑟顿综合征制定一套核心结果:国际多方 e-Delphi 共识研究。
IF 3 3区 医学 Q2 DERMATOLOGY Pub Date : 2025-01-01 Epub Date: 2024-11-01 DOI: 10.1159/000542215
Anouk E M Nouwen, Aviël Ragamin, Maria J Knol, Hagen Ott, Lisa Weibel, Cristina Has, Alain Hovnanian, Amy S Paller, Christine Bodemer, Virgil A S H Dalm, Suzanne G M A Pasmans, Renske Schappin
<p><strong>Introduction: </strong>Netherton syndrome (NS; OMIM#256500) is a rare and severe disorder of epidermal maturation and keratinization caused by pathogenic variants in the serine protease inhibitor Kazal type 5 (SPINK5), leading to severe skin barrier impairment. Although effective treatment is crucial for NS patients, there is a lack of knowledge on what the best treatment options are for these patients. Large heterogeneity in reported outcomes and measurement instruments hinders accurate comparison of treatment results across studies and the development of a treatment guideline. Therefore, we aimed to develop a core outcome set (COS) for NS that can be used in clinical care and research.</p><p><strong>Methods: </strong>This study was performed in accordance with the recommendations of the Core Outcome Measures in Effectiveness Trials (COMET) initiative. After identification of outcomes through a literature search and classification based on the International Classification of Functioning and taxonomies published by the COMET initiative, discussion groups were organized at the 2nd International Netherton Congress 2022 to finalize the provisional outcome list. Through a 2-round e-Delphi, 41 stakeholders (patients and family members, professionals, and representatives of industry) from 14 countries rated the importance of the outcomes using a 9-point Likert scale. An online consensus meeting attended by 14 stakeholders finalized the COS.</p><p><strong>Results: </strong>The COS for NS comprised 21 outcomes in 10 domains. These included four "skin" outcomes, two "sensation" outcomes, two "side-effects of treatment" outcomes, one "vitality" outcome, one "emotional functioning" outcome, two "physical development" outcomes, two "nutrition" outcomes, two "infections" outcomes, two "allergies" outcomes, and three "assessment results" outcomes.</p><p><strong>Conclusion: </strong>In this study, consensus was reached on 21 outcomes to be included in the COS for NS. The selection of outcomes in the COS underlines that NS not only affects the skin but is a disease requiring a broad multidisciplinary approach in clinical care and research. International implementation of this COS will lead to more uniform reporting, thereby enabling comparison of study results, which may facilitate future treatment guideline development. The next step is to further conceptually define the outcomes and reach consensus on how to measure these.</p><p><strong>Introduction: </strong>Netherton syndrome (NS; OMIM#256500) is a rare and severe disorder of epidermal maturation and keratinization caused by pathogenic variants in the serine protease inhibitor Kazal type 5 (SPINK5), leading to severe skin barrier impairment. Although effective treatment is crucial for NS patients, there is a lack of knowledge on what the best treatment options are for these patients. Large heterogeneity in reported outcomes and measurement instruments hinders accurate comparison of treatment resul
导言:奈瑟顿综合征(Netherton syndrome,NS;OMIM#256500)是一种罕见的严重表皮成熟和角质化障碍性疾病,由丝氨酸蛋白酶抑制剂卡扎尔 5 型(SPINK5)的致病变异引起,导致严重的皮肤屏障受损。虽然有效的治疗对 NS 患者至关重要,但目前对这些患者的最佳治疗方案还缺乏了解。报告结果和测量工具的巨大异质性阻碍了对不同研究的治疗结果进行准确比较,也阻碍了治疗指南的制定。因此,我们的目标是制定一套可用于临床治疗和研究的 NS 核心结果集(COS):本研究根据有效性试验核心结果测量(COMET)倡议的建议进行。通过文献检索确定结果,并根据国际功能分类和 COMET 计划发布的分类标准进行分类后,在 2022 年第二届国际奈瑟顿大会上组织了讨论小组,以最终确定临时结果列表。通过两轮电子德尔菲法,来自 14 个国家的 41 名利益相关者(患者和家属、专业人士和行业代表)使用 9 点李克特量表对结果的重要性进行了评分。由 14 位利益相关者参加的在线共识会议最终确定了 COS:NS 核心结果集包括 10 个领域的 21 项结果。其中包括四项 "皮肤 "结果、两项 "感觉 "结果、两项 "治疗副作用 "结果、一项 "活力 "结果、一项 "情绪功能 "结果、两项 "身体发育 "结果、两项 "营养 "结果、两项 "感染 "结果、两项 "过敏 "结果和三项 "评估结果":本研究就 21 项结果达成了共识,这些结果将被纳入 NS 的 COS。COS中的结果选择强调了NS不仅影响皮肤,而且是一种需要在临床护理和研究中采用广泛的多学科方法的疾病。在国际范围内实施该 COS 将使报告更加统一,从而能够对研究结果进行比较,这可能有助于未来治疗指南的制定。下一步是进一步从概念上定义结果,并就如何衡量这些结果达成共识。
{"title":"Developing a Core Outcome Set for Netherton Syndrome: An International Multi-Stakeholder e-Delphi Consensus Study.","authors":"Anouk E M Nouwen, Aviël Ragamin, Maria J Knol, Hagen Ott, Lisa Weibel, Cristina Has, Alain Hovnanian, Amy S Paller, Christine Bodemer, Virgil A S H Dalm, Suzanne G M A Pasmans, Renske Schappin","doi":"10.1159/000542215","DOIUrl":"10.1159/000542215","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;Netherton syndrome (NS; OMIM#256500) is a rare and severe disorder of epidermal maturation and keratinization caused by pathogenic variants in the serine protease inhibitor Kazal type 5 (SPINK5), leading to severe skin barrier impairment. Although effective treatment is crucial for NS patients, there is a lack of knowledge on what the best treatment options are for these patients. Large heterogeneity in reported outcomes and measurement instruments hinders accurate comparison of treatment results across studies and the development of a treatment guideline. Therefore, we aimed to develop a core outcome set (COS) for NS that can be used in clinical care and research.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This study was performed in accordance with the recommendations of the Core Outcome Measures in Effectiveness Trials (COMET) initiative. After identification of outcomes through a literature search and classification based on the International Classification of Functioning and taxonomies published by the COMET initiative, discussion groups were organized at the 2nd International Netherton Congress 2022 to finalize the provisional outcome list. Through a 2-round e-Delphi, 41 stakeholders (patients and family members, professionals, and representatives of industry) from 14 countries rated the importance of the outcomes using a 9-point Likert scale. An online consensus meeting attended by 14 stakeholders finalized the COS.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The COS for NS comprised 21 outcomes in 10 domains. These included four \"skin\" outcomes, two \"sensation\" outcomes, two \"side-effects of treatment\" outcomes, one \"vitality\" outcome, one \"emotional functioning\" outcome, two \"physical development\" outcomes, two \"nutrition\" outcomes, two \"infections\" outcomes, two \"allergies\" outcomes, and three \"assessment results\" outcomes.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;In this study, consensus was reached on 21 outcomes to be included in the COS for NS. The selection of outcomes in the COS underlines that NS not only affects the skin but is a disease requiring a broad multidisciplinary approach in clinical care and research. International implementation of this COS will lead to more uniform reporting, thereby enabling comparison of study results, which may facilitate future treatment guideline development. The next step is to further conceptually define the outcomes and reach consensus on how to measure these.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;Netherton syndrome (NS; OMIM#256500) is a rare and severe disorder of epidermal maturation and keratinization caused by pathogenic variants in the serine protease inhibitor Kazal type 5 (SPINK5), leading to severe skin barrier impairment. Although effective treatment is crucial for NS patients, there is a lack of knowledge on what the best treatment options are for these patients. Large heterogeneity in reported outcomes and measurement instruments hinders accurate comparison of treatment resul","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"35-48"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11793099/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142575339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and Safety of Upadacitinib versus Dupilumab Treatment for Moderate-to-Severe Atopic Dermatitis in Four Body Regions: Analysis from the Heads Up Study. 乌达帕替尼与杜匹单抗治疗四个身体部位中度至重度特应性皮炎的有效性和安全性:抬头研究分析
IF 3 3区 医学 Q2 DERMATOLOGY Pub Date : 2025-01-01 Epub Date: 2024-10-30 DOI: 10.1159/000542275
Jacob P Thyssen, David Rosmarin, Antonio Costanzo, Richard Warren, Chia-Yu Chu, Raj Chovatiya, Barry Ladizinski, Xiaofei Hu, Yingyi Liu, Brian Calimlim, Chudi Nduaka, Namita Vigna, April Armstrong
<p><strong>Introduction: </strong>Upadacitinib has demonstrated high and rapid rates of efficacy in adolescent and adult patients with moderate-to-severe atopic dermatitis (AD) as assessed by the Eczema Area and Severity Index (EASI). This post hoc analysis assessed the EASI response in four anatomical regions for patients with moderate-to-severe AD treated with upadacitinib compared to dupilumab over 24 weeks.</p><p><strong>Methods: </strong>Data from patients randomized 1:1 to receive upadacitinib 30 mg extended-release tablet orally once daily or dupilumab 300 mg by subcutaneous injection every 2 weeks after a loading dose of 600 mg in the Heads Up study were analyzed for achievement of ≥75%, ≥90%, or 100% reduction of EASI in four body regions: (1) head and neck, (2) trunk (including genitals), (3) upper limbs, and (4) lower limbs (including buttocks) at each study visit through week 24. Patient response data from the Head and Neck Patient Global Impression of Severity (HN-PGIS) were also analyzed at each study visit for comparison of upadacitinib to dupilumab.</p><p><strong>Results: </strong>Greater proportions of patients treated with upadacitinib versus dupilumab achieved skin clearance rates of ≥75% (EASI 75) at week 1 and higher clearance rates of ≥90% (EASI 90) or 100% (EASI 100) by week 4 or earlier in all four body regions. This difference was maintained at each visit through week 24 for both EASI 90 and EASI 100. Patient responses on the HN-PGIS indicated that a greater proportion of patients (nominal p value <0.05) treated with upadacitinib compared to dupilumab reported that AD symptoms in the head and neck region were absent or minimal as early as week 1.</p><p><strong>Conclusion: </strong>Compared to dupilumab, upadacitinib treatment provided higher rates of rapid, sustained efficacy for the head and neck, trunk, upper limbs, and lower limbs for the treatment of moderate-to-severe AD as measured by the EASI and supported by patient responses.</p><p><strong>Introduction: </strong>Upadacitinib has demonstrated high and rapid rates of efficacy in adolescent and adult patients with moderate-to-severe atopic dermatitis (AD) as assessed by the Eczema Area and Severity Index (EASI). This post hoc analysis assessed the EASI response in four anatomical regions for patients with moderate-to-severe AD treated with upadacitinib compared to dupilumab over 24 weeks.</p><p><strong>Methods: </strong>Data from patients randomized 1:1 to receive upadacitinib 30 mg extended-release tablet orally once daily or dupilumab 300 mg by subcutaneous injection every 2 weeks after a loading dose of 600 mg in the Heads Up study were analyzed for achievement of ≥75%, ≥90%, or 100% reduction of EASI in four body regions: (1) head and neck, (2) trunk (including genitals), (3) upper limbs, and (4) lower limbs (including buttocks) at each study visit through week 24. Patient response data from the Head and Neck Patient Global Impression of Severity (HN-PGIS) were
简介:根据湿疹面积和严重程度指数(EASI)评估,奥达帕替尼对中重度特应性皮炎(AD)青少年和成人患者的疗效显著且见效快。这项事后分析评估了中重度特应性皮炎患者在接受达达替尼与杜比鲁单抗治疗24周后四个解剖区域的EASI反应:在 "抬起头来 "研究中,患者按1:1比例随机接受达帕替尼30毫克缓释片,每天口服一次,或在600毫克负荷剂量后每2周皮下注射一次杜比鲁单抗300毫克:在第 24 周之前的每次研究访问中,对以下四个身体部位的 EASI 降低情况进行分析:1)头颈部;2)躯干(包括生殖器);3)上肢;4)下肢(包括臀部)。在每个研究访问中,还分析了来自头颈部患者严重程度总体印象(HN-PGIS)的患者反应数据,以比较upadacitinib和dupilumab:与杜比鲁单抗相比,接受达帕替尼治疗的患者在第1周皮肤清除率≥75%(EASI 75)的比例更高,在第4周或更早时,所有四个身体区域的皮肤清除率≥90%(EASI 90)或100%(EASI 100)的比例更高。EASI 90 和 EASI 100 的这一差异在每次就诊时都会保持到第 24 周。患者对HN-PGIS的反应表明,有更大比例的患者(名义p值 结论)在第4周或更早达到100%(EASI 100):与杜比鲁单抗相比,奥达替尼治疗中重度AD在头颈部、躯干、上肢和下肢的快速、持续疗效率更高,这可以通过EASI来衡量,并得到患者反应的支持。
{"title":"Efficacy and Safety of Upadacitinib versus Dupilumab Treatment for Moderate-to-Severe Atopic Dermatitis in Four Body Regions: Analysis from the Heads Up Study.","authors":"Jacob P Thyssen, David Rosmarin, Antonio Costanzo, Richard Warren, Chia-Yu Chu, Raj Chovatiya, Barry Ladizinski, Xiaofei Hu, Yingyi Liu, Brian Calimlim, Chudi Nduaka, Namita Vigna, April Armstrong","doi":"10.1159/000542275","DOIUrl":"10.1159/000542275","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;Upadacitinib has demonstrated high and rapid rates of efficacy in adolescent and adult patients with moderate-to-severe atopic dermatitis (AD) as assessed by the Eczema Area and Severity Index (EASI). This post hoc analysis assessed the EASI response in four anatomical regions for patients with moderate-to-severe AD treated with upadacitinib compared to dupilumab over 24 weeks.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Data from patients randomized 1:1 to receive upadacitinib 30 mg extended-release tablet orally once daily or dupilumab 300 mg by subcutaneous injection every 2 weeks after a loading dose of 600 mg in the Heads Up study were analyzed for achievement of ≥75%, ≥90%, or 100% reduction of EASI in four body regions: (1) head and neck, (2) trunk (including genitals), (3) upper limbs, and (4) lower limbs (including buttocks) at each study visit through week 24. Patient response data from the Head and Neck Patient Global Impression of Severity (HN-PGIS) were also analyzed at each study visit for comparison of upadacitinib to dupilumab.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Greater proportions of patients treated with upadacitinib versus dupilumab achieved skin clearance rates of ≥75% (EASI 75) at week 1 and higher clearance rates of ≥90% (EASI 90) or 100% (EASI 100) by week 4 or earlier in all four body regions. This difference was maintained at each visit through week 24 for both EASI 90 and EASI 100. Patient responses on the HN-PGIS indicated that a greater proportion of patients (nominal p value &lt;0.05) treated with upadacitinib compared to dupilumab reported that AD symptoms in the head and neck region were absent or minimal as early as week 1.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Compared to dupilumab, upadacitinib treatment provided higher rates of rapid, sustained efficacy for the head and neck, trunk, upper limbs, and lower limbs for the treatment of moderate-to-severe AD as measured by the EASI and supported by patient responses.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;Upadacitinib has demonstrated high and rapid rates of efficacy in adolescent and adult patients with moderate-to-severe atopic dermatitis (AD) as assessed by the Eczema Area and Severity Index (EASI). This post hoc analysis assessed the EASI response in four anatomical regions for patients with moderate-to-severe AD treated with upadacitinib compared to dupilumab over 24 weeks.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Data from patients randomized 1:1 to receive upadacitinib 30 mg extended-release tablet orally once daily or dupilumab 300 mg by subcutaneous injection every 2 weeks after a loading dose of 600 mg in the Heads Up study were analyzed for achievement of ≥75%, ≥90%, or 100% reduction of EASI in four body regions: (1) head and neck, (2) trunk (including genitals), (3) upper limbs, and (4) lower limbs (including buttocks) at each study visit through week 24. Patient response data from the Head and Neck Patient Global Impression of Severity (HN-PGIS) were ","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"10-18"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11793090/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142544324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Questionnaire-Based Global Prevalence of Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis. 基于问卷调查的全球化脓性汗腺炎患病率:系统回顾和荟萃分析。
IF 3 3区 医学 Q2 DERMATOLOGY Pub Date : 2024-12-23 DOI: 10.1159/000537920
Jawad Ahmad Zahid, Mattias A S Henning, Dorra Bouazzi, Gregor B E Jemec

Background: Hidradenitis suppurativa (HS), a chronic inflammatory skin disease affecting intertriginous areas, presents a recurring and debilitating challenge. Even though recent efforts have been made to estimate the overall HS prevalence, variations in screening modalities and missing data from the Global South warrant further investigation. Understanding the HS prevalence is crucial for treatment approaches and pathogenesis. Thus, we aimed to estimate a global HS prevalence based on studies using homogeneous validated questions.

Methods: This systematic review was prospectively registered on PROSPERO and adhered to Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Searches in PubMed, Embase, and CINAHL were performed on August 9, 2023. Original reports assessing the HS prevalence in adults using the following two questions were included: "Do you have recurrent boils of the skin?" and "Have you for the past 6 months had 2 or more boils/abscesses in any of the below locations: in the axilla, in the groin, around your genitals, on the buttocks, several locations i.e., first the buttocks then the axilla, etc.?" A pooled prevalence with 95% confidence interval (CI) was calculated with a random-effects model.

Results: Eight studies qualified for inclusion, of which the prevalence estimate ranged from 0.7% to 6.4%. The meta-analysis encompassing 49,971 participants revealed a global HS prevalence of 2.5% (95% CI, 1.8-3.5%).

Conclusion: This meta-analysis suggests a global HS prevalence of 2.5% using a validated questionnaire. Due to heterogeneity and sparse data from the Global South, this estimate should be interpreted with caution.

背景:化脓性汗腺炎(HS)是一种影响三叶间区慢性炎症性皮肤病,是一种复发性和衰弱性的挑战。尽管最近已经做出了努力来估计HS的总体患病率,但筛查方式的差异和全球南方缺失的数据值得进一步调查。了解HS患病率对治疗方法和发病机制至关重要。因此,我们的目的是基于使用同质验证问题的研究来估计全球HS患病率。方法:本系统评价在PROSPERO上前瞻性注册,并遵循系统评价和荟萃分析(PRISMA)指南的首选报告项目。在PubMed, Embase和CINAHL中检索于2023年8月9日进行。使用以下两个问题评估成人HS患病率的原始报告包括:“您是否有复发性皮肤疖子?”和“您在过去6个月内是否在以下任何位置有2个或更多的疖子/脓肿:在腋窝,在腹股沟,在生殖器周围,在臀部,几个位置,即首先是臀部,然后是腋窝等?”采用随机效应模型计算具有95%置信区间(CI)的合并患病率。结果:8项研究符合纳入标准,其中患病率估计范围为0.7%至6.4%。纳入49,971名参与者的荟萃分析显示,全球HS患病率为2.5% (95% CI, 1.8-3.5%)。结论:本荟萃分析表明,使用有效的问卷调查,全球HS患病率为2.5%。由于全球南方的异质性和稀疏数据,应该谨慎解释这一估计。
{"title":"Questionnaire-Based Global Prevalence of Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis.","authors":"Jawad Ahmad Zahid, Mattias A S Henning, Dorra Bouazzi, Gregor B E Jemec","doi":"10.1159/000537920","DOIUrl":"https://doi.org/10.1159/000537920","url":null,"abstract":"<p><strong>Background: </strong>Hidradenitis suppurativa (HS), a chronic inflammatory skin disease affecting intertriginous areas, presents a recurring and debilitating challenge. Even though recent efforts have been made to estimate the overall HS prevalence, variations in screening modalities and missing data from the Global South warrant further investigation. Understanding the HS prevalence is crucial for treatment approaches and pathogenesis. Thus, we aimed to estimate a global HS prevalence based on studies using homogeneous validated questions.</p><p><strong>Methods: </strong>This systematic review was prospectively registered on PROSPERO and adhered to Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Searches in PubMed, Embase, and CINAHL were performed on August 9, 2023. Original reports assessing the HS prevalence in adults using the following two questions were included: \"Do you have recurrent boils of the skin?\" and \"Have you for the past 6 months had 2 or more boils/abscesses in any of the below locations: in the axilla, in the groin, around your genitals, on the buttocks, several locations i.e., first the buttocks then the axilla, etc.?\" A pooled prevalence with 95% confidence interval (CI) was calculated with a random-effects model.</p><p><strong>Results: </strong>Eight studies qualified for inclusion, of which the prevalence estimate ranged from 0.7% to 6.4%. The meta-analysis encompassing 49,971 participants revealed a global HS prevalence of 2.5% (95% CI, 1.8-3.5%).</p><p><strong>Conclusion: </strong>This meta-analysis suggests a global HS prevalence of 2.5% using a validated questionnaire. Due to heterogeneity and sparse data from the Global South, this estimate should be interpreted with caution.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-10"},"PeriodicalIF":3.0,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142881504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Risk of Hospital Admission for an Acute-Onset Psychiatric Disorder in Adolescents and Adults Treated with Isotretinoin: A French, Nationwide, Population-Based, Case-Time-Control Study. 接受异维甲酸治疗的青少年和成人急性发作精神障碍的住院风险:一项法国全国性、基于人群的病例-时间对照研究
IF 3 3区 医学 Q2 DERMATOLOGY Pub Date : 2024-12-21 DOI: 10.1159/000542626
Catherine Droitcourt, Sandrine Kerbrat, Maxime Raby, Claire Laurent, David Travers, Frédéric Balusson, Emmanuel Oger, Alain Dupuy

Introduction: Oral isotretinoin is the only effective treatment for severe acne without an alternative. Isotretinoin has been linked to the occurrence of acute psychiatric disorders outside suicidal behaviors. There are few large-scale epidemiological studies in this area, and the putative associations are unclear. Our objective was to determine whether adolescents and young adults have an elevated risk of acute-onset psychiatric disorder requiring hospital treatment within 2 months of starting isotretinoin treatment.

Methods: Our data source was the French national health insurance database (Système National des Données de Santé, SNDS), 2010-2015. We performed a case-time-control study nested in an exhaustive, nationwide cohort of all French adolescents and young adults aged 10-25 years treated with isotretinoin. The outcome was an acute-onset psychiatric disorder requiring hospitalization (including anxiety, depressive, mood, adjustment, and psychotic disorders). A conditional logistic model was used to estimate odds ratios (ORs) with their 95% confidence interval (CI) for acute psychiatric events.

Results: 2,284 acute-onset psychiatric disorder requiring hospitalization were recorded for the study population of 262,786 patients. Among the patients with at least one psychiatric event, 88 had started taking isotretinoin in the risk period (0-2 months before the date of the event), versus 81 in the reference period (2-4 months before the event). A comparison with the 383 and 355 time-trend matched controls who started taking isotretinoin in the risk and reference periods, respectively, yielded a case-time-control OR (95% CI) of 1.01 (0.72-1.41).

Conclusion: Psychiatric events managed outside the hospital system were not recorded. Our findings are reassuring for clinicians concerning the risk of severe acute-onset psychiatric events after isotretinoin initiation.

口服异维甲酸是治疗严重痤疮的唯一有效方法。异维甲酸与自杀行为之外的急性精神疾病的发生有关。在这一领域很少有大规模的流行病学研究,假定的关联尚不清楚。我们的目的是确定在开始异维甲酸治疗的2个月内,青少年和年轻成人是否有需要住院治疗的急性发作性精神障碍的风险升高。方法数据来源为2010-2015年法国国家健康保险数据库(systemmes national des donnsamuise, SNDS)。我们进行了一项病例-时间-对照研究,该研究嵌套在一个详尽的全国队列中,所有法国青少年和10至25岁的年轻人接受异维甲酸治疗。结果为需要住院治疗的急性精神障碍(包括焦虑、抑郁、情绪、适应和精神障碍)。使用条件逻辑模型估计急性精神事件的优势比(ORs)及其95%置信区间(CI)。结果262786例患者中有2284例需要住院治疗的急性发作性精神障碍。在至少有一次精神事件的患者中,88人在风险期(事件发生前0至2个月)开始服用异维甲酸,而在参考期(事件发生前2至4个月)开始服用异维甲酸。与分别在危险期和参照期开始服用异维A酸的383名和355名时间趋势匹配的对照组进行比较,病例-时间-对照OR (95%CI)为1.01(0.72-1.41)。结论医院系统外处理的精神事件未被记录。我们的研究结果使临床医生对异维甲酸开始后严重急性发作精神事件的风险感到放心。
{"title":"The Risk of Hospital Admission for an Acute-Onset Psychiatric Disorder in Adolescents and Adults Treated with Isotretinoin: A French, Nationwide, Population-Based, Case-Time-Control Study.","authors":"Catherine Droitcourt, Sandrine Kerbrat, Maxime Raby, Claire Laurent, David Travers, Frédéric Balusson, Emmanuel Oger, Alain Dupuy","doi":"10.1159/000542626","DOIUrl":"10.1159/000542626","url":null,"abstract":"<p><strong>Introduction: </strong>Oral isotretinoin is the only effective treatment for severe acne without an alternative. Isotretinoin has been linked to the occurrence of acute psychiatric disorders outside suicidal behaviors. There are few large-scale epidemiological studies in this area, and the putative associations are unclear. Our objective was to determine whether adolescents and young adults have an elevated risk of acute-onset psychiatric disorder requiring hospital treatment within 2 months of starting isotretinoin treatment.</p><p><strong>Methods: </strong>Our data source was the French national health insurance database (Système National des Données de Santé, SNDS), 2010-2015. We performed a case-time-control study nested in an exhaustive, nationwide cohort of all French adolescents and young adults aged 10-25 years treated with isotretinoin. The outcome was an acute-onset psychiatric disorder requiring hospitalization (including anxiety, depressive, mood, adjustment, and psychotic disorders). A conditional logistic model was used to estimate odds ratios (ORs) with their 95% confidence interval (CI) for acute psychiatric events.</p><p><strong>Results: </strong>2,284 acute-onset psychiatric disorder requiring hospitalization were recorded for the study population of 262,786 patients. Among the patients with at least one psychiatric event, 88 had started taking isotretinoin in the risk period (0-2 months before the date of the event), versus 81 in the reference period (2-4 months before the event). A comparison with the 383 and 355 time-trend matched controls who started taking isotretinoin in the risk and reference periods, respectively, yielded a case-time-control OR (95% CI) of 1.01 (0.72-1.41).</p><p><strong>Conclusion: </strong>Psychiatric events managed outside the hospital system were not recorded. Our findings are reassuring for clinicians concerning the risk of severe acute-onset psychiatric events after isotretinoin initiation.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-11"},"PeriodicalIF":3.0,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142876477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of Hidradenitis Suppurativa in Xi'an, China: A Single Center Epidemiological Study. 西安市化脓性汗腺炎流行病学单中心研究
IF 3 3区 医学 Q2 DERMATOLOGY Pub Date : 2024-12-20 DOI: 10.1159/000539019
Danchen Hu, Dorra Bouazzi, Cecilia E Medianfar, Robin Christensen, Gregor B E Jemec, Songmei Geng

Background: Hidradenitis suppurativa (HS), also known as acne inversa, is a chronic, recurrent, and inflammatory disease. HS is fairly rare among the population. This study was a part of the Global Hidradenitis Suppurativa Atlas (GHiSA) initiative, aiming to establish the prevalence of HS, based on a questionnaire and subsequent clinical examination targeting healthy adults accompanying patients undergoing care in a tertiary hospital.

Objective and methods: This study was a monocenter study in tertiary care in, The Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China, and was conducted by the Department of Dermatology. Healthy adults accompanying a patient to the outpatient clinic or hospitalized (Department of Dermatology excluded) were approached and surveyed after agreeing to participation. The data were collected by residents and students and the questionnaire was translated into Chinese.

Results: A total of 552 Chinese participants were eligible for inclusion, consisting of 246 males and 306 females. A total of 515 participants were screened negative through the questionnaire. Twenty-two of the participants screened positive. Of these, four participants who were highly suspected to have HS declined a physical exam. The possibility of HS was ruled out by the collection of detailed medical histories of other participants (n = 16) screened positive. The confirmed prevalence of HS in the remaining 552 participants was 0.36% (95% confidence interval 0.10%-1.31%). Two participants, one male and one female, respectively, were diagnosed with HS. There were no significant differences in the median age, BMI and the percentage of smokers between the control group and the HS group.

Conclusion: The estimated adult HS prevalence rate in Xi'an, China is 0.36%.

背景:化脓性汗腺炎(HS),又称逆痤疮,是一种慢性、复发性、炎症性疾病。HS在人群中相当罕见。本研究是全球化脓性汗腺炎地图集(GHiSA)倡议的一部分,旨在通过问卷调查和随后的临床检查,确定HS的患病率,目标是在三级医院接受治疗的健康成人陪同患者。目的与方法:本研究为中国西安交通大学第二附属医院三级护理单中心研究,由皮肤科开展。在同意参与后,与陪同患者去门诊或住院(皮肤科除外)的健康成年人接触并进行调查。数据由居民和学生收集,问卷翻译成中文。结果:共有552名中国受试者符合纳入条件,其中男性246人,女性306人。通过问卷调查,共有515名参与者被筛选为阴性。22名参与者的筛查结果呈阳性。其中,四名被高度怀疑患有艾滋病的参与者拒绝了体检。通过收集其他参与者(n = 16)筛查阳性的详细病史,排除HS的可能性。其余552名参与者的HS确诊患病率为0.36%(95%置信区间0.10% ~ 1.31%)。两名参与者,一男一女,分别被诊断为HS。对照组和HS组在中位年龄、BMI和吸烟者比例上没有显著差异。结论:西安市成人HS患病率为0.36%。
{"title":"Prevalence of Hidradenitis Suppurativa in Xi'an, China: A Single Center Epidemiological Study.","authors":"Danchen Hu, Dorra Bouazzi, Cecilia E Medianfar, Robin Christensen, Gregor B E Jemec, Songmei Geng","doi":"10.1159/000539019","DOIUrl":"https://doi.org/10.1159/000539019","url":null,"abstract":"<p><strong>Background: </strong>Hidradenitis suppurativa (HS), also known as acne inversa, is a chronic, recurrent, and inflammatory disease. HS is fairly rare among the population. This study was a part of the Global Hidradenitis Suppurativa Atlas (GHiSA) initiative, aiming to establish the prevalence of HS, based on a questionnaire and subsequent clinical examination targeting healthy adults accompanying patients undergoing care in a tertiary hospital.</p><p><strong>Objective and methods: </strong>This study was a monocenter study in tertiary care in, The Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China, and was conducted by the Department of Dermatology. Healthy adults accompanying a patient to the outpatient clinic or hospitalized (Department of Dermatology excluded) were approached and surveyed after agreeing to participation. The data were collected by residents and students and the questionnaire was translated into Chinese.</p><p><strong>Results: </strong>A total of 552 Chinese participants were eligible for inclusion, consisting of 246 males and 306 females. A total of 515 participants were screened negative through the questionnaire. Twenty-two of the participants screened positive. Of these, four participants who were highly suspected to have HS declined a physical exam. The possibility of HS was ruled out by the collection of detailed medical histories of other participants (n = 16) screened positive. The confirmed prevalence of HS in the remaining 552 participants was 0.36% (95% confidence interval 0.10%-1.31%). Two participants, one male and one female, respectively, were diagnosed with HS. There were no significant differences in the median age, BMI and the percentage of smokers between the control group and the HS group.</p><p><strong>Conclusion: </strong>The estimated adult HS prevalence rate in Xi'an, China is 0.36%.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-6"},"PeriodicalIF":3.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142876451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erythema Nodosum in Sarcoidosis: Relationship with Extrathoracic Involvement and Prognostic Significance. 结节性红斑。与胸外受累的关系及预后意义。
IF 3 3区 医学 Q2 DERMATOLOGY Pub Date : 2024-12-19 DOI: 10.1159/000542407
Joaquim Marcoval, Adriana Iriarte, Gemma Rocamora Blanch, Juan Mañá

Introduction: Only a few studies analysed the prognosis significance of erythema nodosum (EN) in sarcoidosis. Our objective was to analyse the prevalence of EN in sarcoidosis, its possible association of EN with extrathoracic sarcoidosis, and its prognostic significance.

Methods: Retrospective study included patients diagnosed with sarcoidosis at Bellvitge University Hospital, Barcelona, Spain, between 1980 and 2017. Patients were followed up prospectively at the sarcoid clinic of the hospital. Patients' medical records were reviewed to obtain the clinical data.

Results: A total of 728 patients (494 women and 234 men, mean age 43.45 years, SD 13,833) were diagnosed with sarcoidosis. Radiological stages were 0 in 68 patients (9.34%), 1 in 434 (59.62%), 2 in 167 (22.94%), 3 in 45 (6.18%), and 4 in 14 (1.92%). Pulmonary fibrosis at 5 years of follow-up was documented in 44 patients. EN was diagnosed in 269 (37%). In 265 cases (98.5%), EN lesions were present at the onset of sarcoidosis and mostly corresponded to radiological stage 1 at diagnosis (82.52%). Among patients with EN, 3/269 (1.11%) had pulmonary fibrosis at 5 years of follow-up (p < 0.001), sarcoidosis activity persisted for more than 5 years in 28/269 (10.41%) (p < 0.001), and oral corticosteroids were required in 48/269 patients (17.84%) (p < 0.001). Patients with EN had a low incidence of severe extrapulmonary involvement.

Conclusion: EN was observed in 37% of sarcoidosis patients, usually at the onset of the disease. Patients with EN-associated sarcoidosis have mainly radiological stage 1 at diagnosis and are at lower risk of chronicity, pulmonary fibrosis, and severe forms of extrathoracic organ involvement.

目前仅有少数研究分析结节性红斑(EN)对结节病的预后意义。我们的目的是分析EN在结节病中的患病率、EN与胸外结节病的可能关系及其预后意义。方法:回顾性研究1980年至2017年在西班牙巴塞罗那Bellvitge大学医院诊断为结节病的患者。在该院肉瘤门诊对患者进行前瞻性随访。通过查阅患者病历,获得临床资料。结果:728例患者(女性494例,男性234例,平均年龄43.45岁,SD 13833例)被诊断为结节病。放射分期68例(9.34%),434例(59.62%),167例(22.94%),45例(6.18%),14例(1.92%)。在5年的随访中,44例患者记录了肺纤维化。269例(37%)被诊断为EN。265例(98.5%)结节病发病时出现EN病变,诊断时多数符合影像学1期(82.52%)。在EN患者中,3/269在5年随访时发生肺纤维化(结论:37%的结节病患者观察到EN,通常在发病时。en相关性结节病患者在诊断时主要为放射学1期,慢性、肺纤维化和严重胸外器官受累的风险较低。
{"title":"Erythema Nodosum in Sarcoidosis: Relationship with Extrathoracic Involvement and Prognostic Significance.","authors":"Joaquim Marcoval, Adriana Iriarte, Gemma Rocamora Blanch, Juan Mañá","doi":"10.1159/000542407","DOIUrl":"10.1159/000542407","url":null,"abstract":"<p><strong>Introduction: </strong>Only a few studies analysed the prognosis significance of erythema nodosum (EN) in sarcoidosis. Our objective was to analyse the prevalence of EN in sarcoidosis, its possible association of EN with extrathoracic sarcoidosis, and its prognostic significance.</p><p><strong>Methods: </strong>Retrospective study included patients diagnosed with sarcoidosis at Bellvitge University Hospital, Barcelona, Spain, between 1980 and 2017. Patients were followed up prospectively at the sarcoid clinic of the hospital. Patients' medical records were reviewed to obtain the clinical data.</p><p><strong>Results: </strong>A total of 728 patients (494 women and 234 men, mean age 43.45 years, SD 13,833) were diagnosed with sarcoidosis. Radiological stages were 0 in 68 patients (9.34%), 1 in 434 (59.62%), 2 in 167 (22.94%), 3 in 45 (6.18%), and 4 in 14 (1.92%). Pulmonary fibrosis at 5 years of follow-up was documented in 44 patients. EN was diagnosed in 269 (37%). In 265 cases (98.5%), EN lesions were present at the onset of sarcoidosis and mostly corresponded to radiological stage 1 at diagnosis (82.52%). Among patients with EN, 3/269 (1.11%) had pulmonary fibrosis at 5 years of follow-up (p < 0.001), sarcoidosis activity persisted for more than 5 years in 28/269 (10.41%) (p < 0.001), and oral corticosteroids were required in 48/269 patients (17.84%) (p < 0.001). Patients with EN had a low incidence of severe extrapulmonary involvement.</p><p><strong>Conclusion: </strong>EN was observed in 37% of sarcoidosis patients, usually at the onset of the disease. Patients with EN-associated sarcoidosis have mainly radiological stage 1 at diagnosis and are at lower risk of chronicity, pulmonary fibrosis, and severe forms of extrathoracic organ involvement.</p>","PeriodicalId":11185,"journal":{"name":"Dermatology","volume":" ","pages":"1-6"},"PeriodicalIF":3.0,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142863582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Dermatology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1